Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

74.79 -3.32 (-4.25%)
Official Closing Price Updated: 6:30 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
75 76 Next >
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
Although they’re not necessarily the most exciting ideas, investors should turn to safe stocks to buy to manage the market’s ambiguity. 
Via InvestorPlace
Week Of June 9: What's In Store For The Markets
The stock market is very similar to the rest of the economy with winners and losers, but many more losers. Many of today’s high-flyers will be unknown ten years from now. 
Via Talk Markets
Topics Economy
Exposures Economy
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Structure Therapeutics has a long way to go before beating Wegovy. 
Via The Motley Fool
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
Novo Nordisk's stock may not look all that expensive when you're focusing on the long-term potential. 
Via The Motley Fool
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run. 
Via InvestorPlace
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments. 
Via Benzinga
Topics ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits 
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
Exposures Economy
Why Quality Investors Should Delve into NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for Investment Opportunities.
Why Quality-Oriented Investors Should Consider NYSE:NVO. 
Via Chartmill
Is Viking Therapeutics Stock a Buy on the Dip?
Short-term thinking is creating an intriguing opportunity for investors. 
Via The Motley Fool
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
The market for treating chronic kidney disease is nearly within reach. 
Via The Motley Fool
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Via Benzinga
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off. 
Via InvestorPlace
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment. 
Via Benzinga
Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock
There's new evidence suggesting the drug will find another large market. 
Via The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
These two drugmakers have a lot more in common than their market-beating potential. 
Via The Motley Fool
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications. 
Via The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs. 
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Is At The Vanguard Of The Weight Drug Revolution
Novo Nordisk is based in Denmark and sells around the world. Its largest market is the U.S., at about 50% of sales. 
Via Talk Markets
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure or falsely labeled semaglutide products. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider. 
Via InvestorPlace
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks. 
Via Benzinga
Topics ETFs
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B by 2030. 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.